UCL researchers recommend AI language models for schizophrenia diagnosis
Automated analysis of language could help diagnose and assess psychiatric conditions
Read More
Tag: schizophrenia
Cardiff University begins study of schizophrenia therapy
The treatment candidate, known as MDI-26478, is a positive allosteric modulator of the AMPA receptor
Read More
Cyclerion reveals data for schizophrenia therapy
Study data demonstrates positive effects of CY6463 on cognition and inflammation
Read More
FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder
Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021
Read More
Psychiatry Consortium funds project investigating new schizophrenia treatments
Project will see the University of Oxford partner with the Earlham Institute, Biogen and Boehringer Ingelheim
Read More
Janssen seeks EU approval for twice-yearly schizophrenia treatment
Extension application is based on results from Janssen’s Route 6 study
Read More
UK mental health services falling behind those for physical health
A new report on current trends in Schizophrenia services in the UK launched by Janssen has found that mental health services are falling behind physical health services.
Read More
Statins may help treat serious mental illness
Statins could bring significant benefits to people with serious mental illnesses such as schizophrenia, bipolar disorder or non-affective psychoses, indicate new findings from UCL-led research.
Read More
Biogen buys Pfizer’s schizophrenia drug
Biogen is buying Pfizer’s experimental drug PF-04958242, which is being developed for cognitive impairment associated with schizophrenia, in a deal that could be worth $590 million.
Read More
Novartis, Pear to develop digital therapies for schizophrenia, MS
Novartis and Pear Therapeutics have signed a deal to develop digital therapeutics for patients with schizophrenia and multiple sclerosis.
Read More
Boehringer ends development of Alzheimer’s candidate
Boehringer Ingelheim is ending development of BI 409306 in Alzheimer’s disease on disappointing mid-stage trial data.
Read More
EU nod for Gedeon’s novel antipsychotic Reagila
European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia.
Read More
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
